相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Logic of the 26S Proteasome
Galen Andrew Collins et al.
CELL (2017)
The Roles of MDM2 and MDMX in Cancer
Orit Karni-Schmidt et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Tetramer Formation of Tumor Suppressor Protein p53: Structure, Function, and Applications
Rui Kamada et al.
BIOPOLYMERS (2016)
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
Nicholas W. Fischer et al.
CELL CYCLE (2016)
Recent advances in the structural biology of the 26S proteasome
Marc Wehmer et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales et al.
NATURE CELL BIOLOGY (2016)
The p53 C Terminus Controls Site-Specific DNA Binding and Promotes Structural Changes within the Central DNA Binding Domain
Oleg Laptenko et al.
MOLECULAR CELL (2015)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
The cytoplasmic side of p53′s oncosuppressive activities
Anna Comel et al.
FEBS LETTERS (2014)
The E3 Ubiquitin Protein Ligase HERC2 Modulates the Activity of Tumor Protein p53 by Regulating Its Oligomerization
Monica Cubillos-Rojas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity
Valerie Lang et al.
MOLECULAR ONCOLOGY (2014)
Constant rate of p53 tetramerization in response to DNA damage controls the p53 response
Giorgio Gaglia et al.
MOLECULAR SYSTEMS BIOLOGY (2014)
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Steven Lin et al.
ELIFE (2014)
Mitochondrial death functions of p53
N. D. Marchenko et al.
MOLECULAR & CELLULAR ONCOLOGY (2014)
Regulating the 20S Proteasome Ubiquitin-Independent Degradation Pathway
Gili Ben-Nissan et al.
BIOMOLECULES (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Repurposing CRISPR/Cas9 for in situ functional assays
Abba Malina et al.
GENES & DEVELOPMENT (2013)
Controlled Access of p53 to the Nucleus Regulates Its Proteasomal Degradation by MDM2
James R. Davis et al.
MOLECULAR PHARMACEUTICS (2013)
Activation and control of p53 tetramerization in individual living cells
Giorgio Gaglia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
RhoGAPs Attenuate Cell Proliferation by Direct Interaction with p53 Tetramerization Domain
Jie Xu et al.
CELL REPORTS (2013)
Mouse models of Mdm2 and Mdm4 and their clinical implications
Shunbin Xiong
CHINESE JOURNAL OF CANCER (2013)
Inhibition of tumor suppressor protein p53-dependent transcription by a tetramerization domain peptide via hetero-oligomerization
Junya Wada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Mutant p53: one name, many proteins
William A. Freed-Pastor et al.
GENES & DEVELOPMENT (2012)
Links between mutant p53 and genomic instability
Walter Hanel et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Cancer-associated p53 Tetramerization Domain Mutants QUANTITATIVE ANALYSIS REVEALS A LOW THRESHOLD FOR TUMOR SUPPRESSOR INACTIVATION
Rui Kamada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
BIMEL, an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation
Ceri M. Wiggins et al.
JOURNAL OF CELL SCIENCE (2011)
Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53
Sridharan Rajagopalan et al.
NUCLEIC ACIDS RESEARCH (2011)
Ubiquitin-independent p53 proteasomal degradation
P. Tsvetkov et al.
CELL DEATH AND DIFFERENTIATION (2010)
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
James J. Manfredi
GENES & DEVELOPMENT (2010)
Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation
Roland Hjerpe et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
The Effects of Phosphomimetic Lid Mutation on the Thermostability of the N-terminal Domain of MDM2
Erin G. Worralll et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
The C terminus of p53 binds the N-terminal domain of MDM2
Masha V. Poyurovsky et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family
Tobias Brandt et al.
BMC GENOMICS (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
p53 ubiquitination by Mdm2: A never ending tail?
Amanda S. Coutts et al.
DNA REPAIR (2009)
p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation
Yoko Itahana et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Susceptibility of p53 Unstructured N Terminus to 20 S Proteasomal Degradation Programs the Stress Response
Peter Tsvetkov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2
Yan Zhu et al.
MOLECULAR CELL (2009)
Cytoplasmic functions of the tumour suppressor p53
Douglas R. Green et al.
NATURE (2009)
Influence of tetramerisation on site-specific post-translational modifications of p53
Lorna J. Warnock et al.
CANCER BIOLOGY & THERAPY (2008)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
Tamara Terzian et al.
GENES & DEVELOPMENT (2008)
Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26
Yaara Ofir-Rosenfeld et al.
MOLECULAR CELL (2008)
Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2
Chen Katz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Ubiquitination and degradation of mutant p53
Natalia Lukashchuk et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation
Christopher L. Brooks et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination
Linghu Nie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation
Mark Sasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
C-terminal modifications regulate MDM2 dissociation and nuclear export of p53
Stephanie Carter et al.
NATURE CELL BIOLOGY (2007)
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation
Mikael S. Lindstrom et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
20S proteasomes and protein degradation by default
Gad Asher et al.
BIOESSAYS (2006)
Dual-site regulation of MDM2 E3-ubiquitin ligase activity
Maura Wallace et al.
MOLECULAR CELL (2006)
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Stewart H. Lecker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
The central region of HDM2 provides a second binding site for p53
GW Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library
T Kawaguchi et al.
ONCOGENE (2005)
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding
S Uhrinova et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Cooperative binding of tetrameric p53 to DNA
RL Weinberg et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2
M Urist et al.
GENES & DEVELOPMENT (2004)
Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5
MS Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2
MY Li et al.
SCIENCE (2003)
Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination
K O'Keefe et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo
H Shimizu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers - Implications on the dominant negative effect
CD Nicholls et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A peptide that binds and stabilizes p53 core domain:: Chaperone strategy for rescue of oncogenic mutants
A Friedler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53
DP Xirodimas et al.
EXPERIMENTAL CELL RESEARCH (2001)
The role of tetramerization in p53 function
P Chène
ONCOGENE (2001)
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53
ZK Yu et al.
ONCOGENE (2000)
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation
MS Rodriguez et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The MDM2 RING-finger domain is required to promote p53 nuclear export
RK Geyer et al.
NATURE CELL BIOLOGY (2000)
Rapid destruction of human Cdc25A in response to DNA damage
N Mailand et al.
SCIENCE (2000)
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53
SY Fang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
